Spots Global Cancer Trial Database for TAK-700 in Castration Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TAK-700 in Castration Resistant Prostate Cancer
Official Title: Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.
Study ID: NCT01658527
Conditions
Study Description
Brief Summary: The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who failed 1st line treatment with LHRH (luteinizing hormone-releasing hormone) agonists or surgical castration.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Onze Lieve Vrouw Ziekenhuis, Aals, , Belgium
Cliniques Universitaires Saint-Luc, Brussels, , Belgium
AZ Groeninge Kortrijk - Campus Vercruysselaan, Kortrijck, , Belgium
CHU Dinant Godinne - UCL Namur, Yvoir, , Belgium
Contact Details
Name: Cora Sternberg
Affiliation: San Camillo Forlanini Hospitals, Rome, Italy
Role: PRINCIPAL_INVESTIGATOR
Name: Bertrand Tombal
Affiliation: Cliniques Universitaires de St Luc, Brussels, Belgium
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
